Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) announced that the underwriters of its stock offering have exercised their option to purchase 1.1 million additional shares, bringing the overall size of the deal to 8.6 million shares worth a total of $220.0 million. The Cambridge, MA-based developer of the hepatitis C drug telaprevir last week priced 7.5 million shares at $25.50 apiece, for a total of $191.3 million.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
